Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. (PCSA) on January 6, 2022, covering the event date of January 1, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than financial performance.
Material Changes
Effective January 1, 2022, the Company amended its Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 30,000,000 to 50,000,000 shares. This amendment was previously approved by stockholders at a Special Meeting held on November 3, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the material modification to the rights of security holders regarding the increase in authorized share capital.
Investor Verification Checklist
- Verify the effective date of the share authorization increase (January 1, 2022).
- Confirm the new total authorized common shares (50,000,000) versus the prior amount (30,000,000).
- Review the attached Exhibit 3.1 for the full text of the Certificate of Amendment.
- Check subsequent filings for any actual issuance of shares from the newly authorized pool.